Michael Grondine

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Sonya Zabludoff, Chun Deng, Michael Grondine et al. · Molecular Cancer Therapeutics · 2008 · 407 citations · Full text

Cell Death, Cell Cycle, Cancer Biology +17

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia

Erika Krasnickas Keeton, Kristen McEachern, Keith Dillman et al. · Blood · 2013 · 240 citations

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Sylvie M. Guichard, Jon Curwen, Teeru Bihani et al. · Molecular Cancer Therapeutics · 2015 · 125 citations · Full text

Breast Oncology, Chemoprevention Strategy, Pharmacotherapy +18

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL

Tabea Erdmann, Pavel Klener, James T. Lynch et al. · Blood · 2017 · 103 citations · Full text

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i> -Mutant Non–Small Cell Lung Cancer

Dennis O. Adeegbe, Shengwu Liu, Maureen M. Hattersley et al. · Cancer Immunology Research · 2018 · 100 citations · Full text